Sionna Therapeutics (NASDAQ:SION) Shares Up 5.3% – Time to Buy?

Sionna Therapeutics, Inc. (NASDAQ:SION)’s share price rose 5.3% on Friday . The stock traded as high as $48.05 and last traded at $47.67. Approximately 303,922 shares changed hands during mid-day trading, a decline of 19% from the average daily volume of 375,250 shares. The stock had previously closed at $45.29.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. JonesTrading lifted their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a research note on Tuesday, April 28th. Freedom Capital downgraded shares of Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Citizens Jmp restated a “market outperform” rating and issued a $63.00 price target on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Finally, Wedbush assumed coverage on shares of Sionna Therapeutics in a report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.22.

Sionna Therapeutics Stock Performance

The firm has a market capitalization of $2.26 billion, a P/E ratio of -26.03 and a beta of 1.33. The firm has a 50 day simple moving average of $40.64 and a two-hundred day simple moving average of $39.57.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.52) by ($0.08). Sell-side analysts anticipate that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 184,639 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $46.22, for a total transaction of $8,534,014.58. Following the completion of the sale, the director directly owned 2,671,822 shares of the company’s stock, valued at approximately $123,491,612.84. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 184,639 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $46.22, for a total value of $8,534,014.58. Following the completion of the transaction, the director directly owned 2,671,822 shares in the company, valued at approximately $123,491,612.84. This represents a 6.46% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 995,526 shares of company stock valued at $45,249,973. 5.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG increased its stake in shares of Sionna Therapeutics by 4.5% during the 4th quarter. Deutsche Bank AG now owns 10,029 shares of the company’s stock worth $413,000 after purchasing an additional 433 shares during the last quarter. Bank of America Corp DE grew its holdings in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock valued at $192,000 after purchasing an additional 529 shares during the period. MetLife Investment Management LLC increased its position in Sionna Therapeutics by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company’s stock worth $352,000 after buying an additional 532 shares during the last quarter. BNP Paribas Financial Markets increased its position in Sionna Therapeutics by 35.2% in the third quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after buying an additional 619 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Sionna Therapeutics in the fourth quarter valued at $36,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.